Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOXIRI vs Chemoradiotherapy in EMVI+ Locally Advanced Rectal Cancer
NCT04423965Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of folinic acid + 5-fluorouracil + oxaliplatin + irinotecan in locally advanced rectal cancer (LARC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
folinic acid + 5-fluorouracil + oxaliplatin + irinotecan
03
Conditions
locally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on NCT04423965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423965.